MX2010001577A - Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. - Google Patents
Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.Info
- Publication number
- MX2010001577A MX2010001577A MX2010001577A MX2010001577A MX2010001577A MX 2010001577 A MX2010001577 A MX 2010001577A MX 2010001577 A MX2010001577 A MX 2010001577A MX 2010001577 A MX2010001577 A MX 2010001577A MX 2010001577 A MX2010001577 A MX 2010001577A
- Authority
- MX
- Mexico
- Prior art keywords
- egfr inhibitor
- inhibitor treatment
- predictive marker
- predictive
- marker
- Prior art date
Links
- 229940121647 egfr inhibitor Drugs 0.000 title abstract 2
- 239000003550 marker Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona un biomarcador el cual es predictivo para el beneficio clínico del tratamiento con inhibidor de EGFR en pacientes con cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114300 | 2007-08-14 | ||
| PCT/EP2008/006522 WO2009021683A2 (en) | 2007-08-14 | 2008-08-07 | Predictive marker for egfr inhibitor treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010001577A true MX2010001577A (es) | 2010-06-02 |
Family
ID=40227519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010001577A MX2010001577A (es) | 2007-08-14 | 2008-08-07 | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110245279A1 (es) |
| EP (1) | EP2179058A2 (es) |
| JP (1) | JP2010535523A (es) |
| KR (1) | KR20100044851A (es) |
| CN (1) | CN101946007A (es) |
| AU (1) | AU2008286336A1 (es) |
| BR (1) | BRPI0814354A2 (es) |
| CA (1) | CA2695247A1 (es) |
| MX (1) | MX2010001577A (es) |
| WO (1) | WO2009021683A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI859118B (zh) * | 2017-03-29 | 2024-10-21 | 大陸商中美冠科生物技術(太倉)有限公司 | 測定對胃癌之西妥昔單抗(cetuximab)敏感性的系統及方法 |
| US20220026415A1 (en) * | 2018-11-26 | 2022-01-27 | National Cancer Center | A method for screening a therapeutic agent for cancer using binding inhibitor of cyclin-dependent kinase 1 (cdk1)-cyclin b1 and retinoic acid receptor responder 1 (rarres1) gene knockout animal model |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1636380A2 (en) * | 2003-05-30 | 2006-03-22 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| KR101126560B1 (ko) * | 2003-05-30 | 2012-04-05 | 도꾜 다이가꾸 | 약제 반응 예측 방법 |
| US20060019284A1 (en) * | 2004-06-30 | 2006-01-26 | Fei Huang | Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells |
-
2008
- 2008-08-07 EP EP08785428A patent/EP2179058A2/en not_active Ceased
- 2008-08-07 AU AU2008286336A patent/AU2008286336A1/en not_active Abandoned
- 2008-08-07 MX MX2010001577A patent/MX2010001577A/es not_active Application Discontinuation
- 2008-08-07 CN CN2008801025831A patent/CN101946007A/zh active Pending
- 2008-08-07 US US12/672,954 patent/US20110245279A1/en not_active Abandoned
- 2008-08-07 JP JP2010520471A patent/JP2010535523A/ja active Pending
- 2008-08-07 WO PCT/EP2008/006522 patent/WO2009021683A2/en not_active Ceased
- 2008-08-07 CA CA2695247A patent/CA2695247A1/en not_active Abandoned
- 2008-08-07 BR BRPI0814354-4A2A patent/BRPI0814354A2/pt not_active Application Discontinuation
- 2008-08-07 KR KR1020107003318A patent/KR20100044851A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008286336A1 (en) | 2009-02-19 |
| EP2179058A2 (en) | 2010-04-28 |
| WO2009021683A8 (en) | 2010-06-17 |
| KR20100044851A (ko) | 2010-04-30 |
| WO2009021683A3 (en) | 2009-04-09 |
| WO2009021683A2 (en) | 2009-02-19 |
| JP2010535523A (ja) | 2010-11-25 |
| CA2695247A1 (en) | 2009-02-19 |
| US20110245279A1 (en) | 2011-10-06 |
| CN101946007A (zh) | 2011-01-12 |
| BRPI0814354A2 (pt) | 2015-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
| ZA200702973B (en) | Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| IN2012DN03012A (es) | ||
| WO2008008430A3 (en) | Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases | |
| JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
| CR20110560A (es) | Métodos de tratamiento para tumores sólidos | |
| CR9301S (es) | Cuerpo de grifo | |
| MX2013003880A (es) | Metodo para diagnostico, pronostico y tratamiento de la metastasis de carcer de mama. | |
| WO2008031551A3 (en) | Non-neuroendocrine cancer therapy | |
| FR2912304B1 (fr) | Instrument de reduction de fracture de corps osseux. | |
| MX2011011431A (es) | Composicion para el tratamiento de cancer de prostata. | |
| EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
| MX2010001571A (es) | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. | |
| WO2010015538A3 (en) | Predictive marker for egfr inhibitor treatment | |
| WO2008054598A8 (en) | Panel of biomarkers for prediction of fti efficacy | |
| MX2010001573A (es) | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. | |
| MX2010001577A (es) | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. | |
| MX2010001583A (es) | Maracdor predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. | |
| BR112013009143A2 (pt) | método in vitro, uso e invenção | |
| MX2010001570A (es) | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. | |
| MX2010001578A (es) | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. | |
| MX2010001572A (es) | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. | |
| MX2010001579A (es) | Maracador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. | |
| MX2010001582A (es) | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |